Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension

Pediatric Drugs

Volumn 11, Issue 2, 2009, Pages 115-128

  Tulloh, Robert ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BERAPROST; BOSENTAN; CLONIDINE; CORTICOSTEROID; FENTANYL; ILOPROST; NIFEDIPINE; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; RHO KINASE INHIBITOR; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; WARFARIN;

BLEEDING; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DRUG MECHANISM; EISENMENGER COMPLEX; EXTRACORPOREAL OXYGENATION; HUMAN; HYPOTENSION; HYPOXIA; INTRAUTERINE INFECTION; LIVER DYSFUNCTION; LUNG EMBOLISM; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; METHEMOGLOBINEMIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SKIN IRRITATION; VISUAL DISORDER;

ADMINISTRATION, ORAL; CHILD; EPOPROSTENOL; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; OXYGEN; OXYGEN INHALATION THERAPY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSTAGLANDINS; PURINES; RECEPTORS, ENDOTHELIN; SULFONES;

EID: 62949083476     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200911020-00003     Document Type: Review

References (97)

1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ 1958; 2: 701-9
2. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension: I. Clinical and hemodynamic study. Am J Med 1951; 11 (6): 686-705
3. Eisenmenger V. Die angeboren defects des kammerscheidewand des herzen. Z Klin Med 1897; 32: 1-28
4. Heath D, Edwards J. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac defects. Circulation 1958; 18: 533-47
5. Rabinovitch M, Keane J, Norwood W. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary haemodynamic findings after repair of congenital heart defects. Circulation 1984; 69: 655-67
6. Rabinovitch M. Pathobiology of pulmonary hypertension: impact on clinical management. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2000; 3: 63-81
7. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc 2006; 3 (1): 111-5
8. Andrews R, Tulloh R. Pulmonary hypertension in paediatrics. Curr Opin Ped 2002; 14: 603-5
9. Kovesi T, Abdurahman A, Blayney M. Elevated carbon dioxide tension as a predictor of subsequent adverse events in infants with bronchopulmonary dysplasia. Lung 2006; 184 (1): 7-13
10. Gibbs J. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86 Suppl. 1: 1-13
11. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension, Venice, Italy, 23-25 Jun 2003. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 1S-90S
12. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 5S-12S
13. Abman SH. Pathogenesis and treatment of neonatal and postnatal pulmonary hypertension. Curr Opin Pediatr 1994; 6 (3): 239-47
14. Humbert M, Nunes H, Sitbon O, et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22 (3): 459-75
15. Luchese S, Manica JL, Zielinsky P. Intrauterine ductus arteriosus constriction: analysis of a historic cohort of 20 cases. Arq Bras Cardiol 2003; 81 (4): 405-10, 399-404
16. Carlo WF, Villamor E, Ambalavanan N, et al. Chronic exposure to cigarette smoke extract impairs endothelium-dependent relaxation of chicken embryo pulmonary arteries. Biol Neonate 2001; 80 (3): 247-50
17. Chambers CD, Hernandez-Diaz S, Li VM, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-87
18. Rosenzweig EB, Barst RJ. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis 2002; 45: 129-38
19. Andrews R, Tulloh R, Magee A, et al. Atrial septal defect with failure to thrive in infancy: hidden pulmonary vascular disease? Pediatr Cardiol 2002; 23 (5): 528-30
20. Haworth SG. Development of the normal and hypertensive pulmonary vasculature. Exp Physiol 1995; 80 (5): 843-53
21. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg 1996; 112 (6): 1600-7; discussion 1607-9
22. Kumar A, Taylor GP, Sandor GG, et al. Pulmonary vascular disease in neonates with transposition of the great arteries and intact ventricular septum. Br Heart J 1993; 69 (5): 442-5
23. Anderson RH, Baker EJ, McCartney FJ, et al., editors. Paediatric cardiology. 2nd ed. London: Churchill Livingstone, 2002
24. Holcomb R, Tyson R, Ivy D, et al. Congenital pulmonary venous stenosis presenting as persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 1999; 28: 301-6
25. Ricci M, Elliott M, Cohen GA, et al. Management of pulmonary venous obstruction after correction of TAPVC: risk factors for adverse outcome. Eur J Cardiothorac Surg 2003; 24 (1): 28-36; discussion 36
26. Rabinovitch M, Haworth S, Castaneda AR, et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978; 58: 1107-22
27. Meyrick B, Reid L. Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am J Pathol 1980; 101: 527-37
28. Rabinovitch M, Bothwell T, Hayakawa B. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986; 55: 632-53
29. Taipale J, Lohi J. Humanmast cell chymase and leukocyte elastase release latent transforming growth factor B1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270: 4689-96
30. Jones P, Cowan K, Rabinovitch M. Induction of tenascin and fibronectin are features associated with increased smooth muscle cell proliferation during the development of progressive pulmonary hypertension in children. Am J Pathol 1997; 150: 1349-60
31. Thomson J, Machado R, Pauciulo M, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-2, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-5
32. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-family signalling. Nature 2003; 425: 577-84
33. Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004; 24 (3): 371-4
34. Rosenzweig EB, Barst RJ. Idiopathic pulmonary arterial hypertension in children. Curr Opin Pediatr 2005; 17 (3): 372-80
35. Manes A, Campana C. Pulmonary hypertension: classification and diagnostic algorithm. Ital Heart J 2005; 6 (10): 834-9
36. Hattle L. Noninvasive assessment and differentiation of left ventricular outflow obstruction with Doppler ultrasound. Circulation 1981; 64: 381-7
37. Ebeid MR, Ferrer PL, Robinson B, et al. Doppler echocardiographic evaluation of pulmonary vascular resistance in children with congenital heart disease. J Am Soc Echocardiogr 1996; 9 (6): 822-31
38. Bossone E, Bodini BD, Mazza A, et al. Pulmonary arterial hypertension: the key role of echocardiography. Chest 2005; 127: 1836-43
39. Lopez-Candales A, Dohi K, Rajagopalan N, et al. Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class. Cardiovasc Ultrasound 2005; 3: 23-6
40. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92 (5): 664-70
41. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4 (1): 23-30
42. Atz AM, Adatia I, Lock JE, et al. Combined effects of nitric oxide during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33: 813-9
43. Mikhail G, Gibbs J, Richardson M, et al. An evaluation of nebulized prostacycin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997; 18: 1499-504
44. Holcomb SS. Understanding pulmonary arterial hypertension. Nursing 2004; 34 (9): 50-4
45. Sigurdsson G, Troughton RW, Xu XF, et al. Detection of pulmonary vein stenosis by transesophageal echocardiography: comparison with multidetector computed tomography. Am Heart J 2007; 153 (5): 800-6
46. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47: 763-6
47. Muthurangu V, Taylor A, Tulloh R, et al. Novel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow. Circulation 2004; 110 (7): 826-34
48. Muthurangu V, Atkinson D, Sermesant M, et al. Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization. Am J Physiol Heart Circ Physiol 2005; 289 (3): H1301-6
49. Tulloh R, Hislop A, Boels P, et al. Chronic hypoxia inhibits postnatal maturation of porcine intrapulmonary artery relaxation. Am J Physiol 1997; 272: H2436-45
50. Black SM, Bekker JM, McMullan DM, et al. Alterations in nitric oxide production in 8-week-old lambs with increased pulmonary blood flow. Pediatr Res 2002; 52 (2): 233-44
51. Adatia I, Haworth S. Circulating endothelin levels in children with congenital heart disease. Br Heart J 1993; 69: 233-6
52. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect RV systolic dysfunction in pulmonary hypertension. Eur Respir J 2007; 29 (4): 737-44
53. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005; 111 (5): 534-8
54. Lindberg L, Olsson AK, Jogi P, et al. How common is severe pulmonary hypertension after pediatric cardiac surgery? J Thorac Cardiovasc Surg 2002; 123 (6): 1155-63
55. Ohsumi H, Sakamoto M, Yamazaki T, et al. Effects of fentanyl on carotid sinus baroreflex control of circulation in rabbits. Am J Physiol 1989; 256: R625-31
56. Levy M, Tulloh RMH, Komai H, et al. Maturation of the contractile response and its endothelial modulation in newborn porcine intrapulmonary arteries. Pediatr Res 1995; 38: 25-9
57. Adatia I, Wessel DL. Therapeutic use of inhaled nitric oxide. Curr Opin Pediatr 1994; 6 (5): 583-90
58. Abman SH. Neonatal pulmonary hypertension: a physiologic approach to treatment. Pediatr Pulmonol 2004; 26 Suppl.: 127-8
59. Hermon M, Golej J, Burda G, et al. Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: a case control study. Artif Organs 1999; 23: 975-8
60. Kinsella JP, Abman SH. Inhaled nitric oxide therapy in children. Paediatr Respir Rev 2005; 6 (3): 190-8
61. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70 (2): 174-8
62. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 56S-61S
63. Clark RH, Huckaby JL, Kueser TJ, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol 2003; 23 (4): 300-3
64. Adatia I, Perry S, Landzberg M, et al. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol 1995; 25 (7): 1656-64
65. Wimmer M, Schlemmer M. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. Cardiovasc Drugs Ther 1992; 6 (2): 183-6
66. McMahon CJ, Kadkin J, Nihill MR. Rapid regression of primary pulmonary hypertension. Heart 2001; 86 (1): E1
67. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111 (24): 3274-80
68. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92: 1702-12
69. Atz AM, Lefler AK, Fairbrother DL, et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002; 124 (3): 628-9
70. Bharani A, Mathew V, Sahu A, et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003; 55 (1): 55-9
71. Brun H, Holmstrom H, Thaulow E. Sudden death during a change in treatment for pulmonary hypertension. Cardiol Young 2005; 15 (2): 223-5
72. Della Torre F, Della Torre E, Di Berardino F. Sildenafil in pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (1): 78-9
73. Matot I, Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 2004; 125 (2): 644-51
74. Cacoub P, Dorent R, Nataf P, et al. Endothelin-1 in pulmonary hypertension. N Engl J Med 1993; 329 (26): 1967-8
75. Rosenzweig EB, Ivy DD, Dingemanse J, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46 (4): 697-704
76. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73 (4): 372-82
77. Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005; 98 (1): 147-51
78. Apostolopoulou SC, Rammos S. Sitaxsentan in pulmonary arterial hypertension. Chest 2003; 123 (5): 1772; author reply 1772-3
79. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169 (4): 441-7
80. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121 (6): 1860-8
81. Prostacyclin: basic principles and clinical application in congestive heart failure and primary pulmonary hypertension. Proceedings of a symposium in Bologna, Italy, November 20, 1993. Am J Cardiol 1995; 75 (3): 1A-73A
82. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334 (5): 296-302
83. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (6): 800-4
84. Vizza CD, Sciomer S, Morelli S, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001; 86 (6): 661-5
85. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41 (12): 2119-25
86. Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother 2005; 39 (7-8): 1265-74
87. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-10
88. Mogollon MV, Lage E, Cabezon S, et al. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation [case report]. Transplant Proc 2006; 38 (8): 2522-3
89. Driscoll JA, Chakinala MM. Medical therapy for pulmonary arterial hypertension. Expert Opin Pharmacother 2008; 9 (1): 65-81
90. Arima M, Kanoh T, Takagi A, et al. Clinical features of acute pulmonary thromboembolism in younger patients. Circ J 2003; 67 (4): 330-3
91. Tanaka E, Harigai M, Tanaka M, et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29 (2): 282-7
92. Cheever KH. An overview of pulmonary arterial hypertension: risks, pathogenesis, clinical manifestations management. J Cardiovasc Nurs 2005; 20 (2): 108-16; quiz 117-8
93. National pulmonary hypertension centres of the UK and Ireland: consensus statement on the management of pulmonary hypertension in the UK and Ireland. Heart 2008; 94: 1-41
94. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327 (2): 76-81
95. Higenbottam T. Intravenous epoprostenol for primary pulmonary hypertension [letter]. N Engl J Med 1996; 334 (22): 1477; author reply 1477-8
96. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164 (9): 1682-7
97. Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91 (7): 2028-35